🇺🇸 FDA
Pipeline program

CISPLATIN, TAGRISSO 40 mg film-coated tablets, Datopotamab deruxtecan, TAGRISSO 80 mg film-coated tablets, CARBOPLATIN, PEMETREXED

D516KC00001

Phase 3 small_molecule active

Quick answer

CISPLATIN, TAGRISSO 40 mg film-coated tablets, Datopotamab deruxtecan, TAGRISSO 80 mg film-coated tablets, CARBOPLATIN, PEMETREXED for Non squamous non-small cell lung cancer (NSCLC) is a Phase 3 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).

Program details

Company
AstraZeneca AB
Indication
Non squamous non-small cell lung cancer (NSCLC)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials